[Skip to content]

Print this page

NICE Technology Appraisals

This is a list of the published NICE technology appraisals. Technology appraisals are recommendations on the use of new and existing medicines and treatments within the NHS.

NICE TAs: 1-20;  21-4041-6061-8081-100101-120121-140141-160161-180181-200201-220221-240;  241-260 261-280; 281-300; 301-320; 341-360; 361-380


NICE TAs 321-340






DHFT Formulary link


East Midlands Cancer Network link (cancer drugs only)

TA 321           Dabrafenib - skin cancer    EMCN algorithm
TA 322

 Lenalidomide for treating myelodysplastic syndromes

   EMCN algorithm
TA 323

Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy

9.1.2 - 9.1.6 Megaloblastic, hypoplastic, haemolytic and renal anaemias 


TA 324

Dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block


No drug implications
TA 325

Nalmefene for reducing alcohol consumption in people with alcohol dependence

4.10 Substance abuse


TA 326

Imatinib for the adjuvant treatment of gastrointestinal stromal tumours

  EMCN guidelines
EMCN algorithm
TA 327

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism.

  2.8 Anticoagulants


Idelasilib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal)

Not recommended by NICE


Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy

1.5 Treatment of chronic diarrhoeas


Sofosbuvir for treating chronic hepatitis C

5.3.3 Viral Hepatitis


Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C

 5.3.3 Viral Hepatitis


Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer

Not recommended by NICE


Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment

   EMCN guidelines

Regorafenib for metastatic colorectal cancer after treatment for metastatic disease

Not recommended by NICE


Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome

2.8.2 Oral anticoagulants



Empagliflozin in combination therapy for treating type 2 diabetes Other anti-diabetics 


Rifaximin for preventing episodes of overt hepatic encephalopathy

5.1.7 Antibacterial: Some other antibiotics, trimethoprim, antituberculous drugs


Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib

  Not approved; available only via CDF

Omalizumab for previously treated chronic spontaneous urticaria

3.4.2 Allergen Immunotherapy


Ustekinumab for treating active psoriatic arthritis

10.1.3 Drugs which suppress the rheumatic disease process